Abstract compliance document light table, generative still for Andrew Hillman
Business Consultant · Strategic Advisor · Dallas, Texas

Business consultant. Strategic advisor. Dallas.

Andrew Hillman advises healthcare, biotech, and investor-backed ventures. This site is the advisory practice: growth consulting and regulatory strategy.

Scroll
Andrew Hillman speaking at an evening event in Dallas
Andrew J. Hillman · Andrew Hillman Dallas · Dallas, Texas
Verified in the public record

No press logos are claimed. The operating record stands on primary public sources.

Who I am
An advisor who has run the science, the pathway, and the capital inside the same companies.
Andrew Jonathan Hillman is a Dallas advisor and the principal of Hillman Ventures, a private family office he founded in 1995. He has built and exited operating companies across surgical hospitals, clinical laboratories, pharmacy, intraoperative neuromonitoring, and medical devices, and now advises founders, investors, and boards on the decisions that determine whether a regulated healthcare company reaches the market.
The advice comes from someone who has been accountable for the outcome, not only for the memo.
Andrew Hillman: driving 30 years of business innovation.
What I do

Two services. One operator.

Each engagement starts with the constraint that is actually holding the business back, then works the problem in the order that money and regulators respond to.

01

Business growth consulting

Revenue, margin, and operating discipline for clinics, practices, diagnostics groups, and investor-backed healthcare services. Fix what is leaking before adding what is new.

Business growth consulting for healthcare and biotech
02

Regulatory strategy

Pathway mapping, milestone planning, and pressure-testing the clinical, operational, and compliance plan before it meets a regulator. Strategy support, not legal advice.

Regulatory strategy advisory for FDA-regulated ventures
The front door

The Diagnostic Advisory Engagement.

New clients start with a short, paid Diagnostic Advisory Engagement. In that engagement I assess your growth performance and your regulatory position together, because in an FDA-regulated business they are one system. What the regulator lets you do decides what you can sell and when you can sell it. A growth plan built without that constraint is a forecast, not a plan.

Step one

Kickoff session

We set the objective, the constraints, and what a useful answer looks like for you.

Step two

Document and data review

I go through what the business actually shows rather than what the deck says.

Step three

Working session

We test the findings against your reality and pressure the options together.

Step four

Final readout

The written strategy report lands, and we walk it end to end.

The engagement ends with a written strategy report and a live strategy session. The report gives you a clear picture of your growth performance and your regulatory position, and of how each one is constraining the other. The session turns that picture into concrete decisions and next steps. The report is something you can take to your board, your investors, and your counsel.

After the diagnostic, we either move into focused work on growth or on regulatory strategy, or you take the findings and act on them with your own team. The diagnostic stands on its own. It is not a sales call with a fee attached.

The Diagnostic Advisory Engagement
Discipline with capital is treated as a competitive advantage, not a constraint.
Operating principle
How I work

The decision sequence.

Recommendations follow a fixed order. Documented facts outrank narrative, and where the evidence is thin, the recommendation says so.

Step 01

Pathway first

The regulatory pathway is settled before anything else. It sets the requirements every later decision answers to.

Step 02

Test the evidence

Scientific and regulatory claims are weighed against primary sources, filings, and the published literature.

Step 03

Plan the capital

The capital plan is built to the pathway, with burn discipline and an operating cadence that matches the stage.

Step 04

Team and execution

The team and execution risk are tested against the plan. Assumptions are stated so a reader can check them.

Andrew Hillman. Keep Calm and Follow The Rules.
Keep Calm and Follow The Rules.

Advisory work stays inside written scope and existing regulatory rules.

Operating history

The advice rests on a documented operating record.

1995
year Hillman Ventures was founded in Dallas

The operating history behind this advisory is documented in primary public sources, including SEC EDGAR filings and the CMS provider registry.

Work history

Current roles and past companies.

Facts from the public record. Past means exited or sold. No ownership percentages are stated.

CURRENT
Principal, Hillman Ventures. A Dallas biotech family office, founded in 1995.
Senior paralegal and healthcare compliance and regulatory expert witness, retained through counsel. Not an attorney.
PAST · Hospitals
Victory Healthcare / Victory Medical Center facilities. Past ownership. Former Victory Hospitals were later acquired by Nobilis Health (2015).
Dynacq Healthcare / Vista Hospital / SSHA. Past hospital ownership.
PAST · Devices
Bone Solutions, Inc., Southlake, Texas. April 2016–November 2021.
PAST · Pharmacies (sold or exited)
The Apothecary Shop (Dallas; sold; now Executive Health, LLC); Progressive Pharma / Altus Pharmacy (Houston); Super Frisco Pharmacy / Centennial / Frisco Pharmacy (Frisco).
PAST · Laboratories (exited)
Gulf Coast Toxicology; Central Texas Toxicology; East Texas Toxicology; National Toxicology; Digestive Laboratories; Quality Lab Partners.
PAST · Anesthesia and staffing (exited)
Prime Anesthesia Staffing; First Assisting Specialists of Texas; L2 Surgical.
PAST · Holding and management (exited)
RHZ, LLC; Optimized, Inc.; Advanced Total Management; Energized, LLC; Forge Realty Partners.

Source: andrewhillmanrecord.com.

Inquire

Start with a Diagnostic Advisory Engagement.

A brief qualifying exchange comes first, so we both know the diagnostic is the right use of your money. The fee is set out in the proposal, not on this page.

Andrew Hillman Advisory
Dallas, Texas, United States
Engagements are established only through a separate written agreement.
The Diagnostic Advisory Engagement
Connect on LinkedIn
Hillman Ventures
The Hillman Letter

Operator notes for advisory work.

Selected Letter essays on pathway, CMC, RMAT, Pre-IND, and grey-market enforcement. Strategy support, not legal advice.

The Hillman Letter · 2026-08-16
The Permission Gap
Twelve states rewrote regenerative medicine law in eighteen months. Federal law did not move. Here is what that costs you.
Read on Substack →
The Hillman Letter · 2026-07-27
The CMC chasm. Why most biotech IND submissions fail at chemistry, not biology.
The biology is usually right.
Read on Substack →
The Hillman Letter · 2026-06-29
When RMAT designation actually helps you. And when it is a marketing pin.
The Regenerative Medicine Advanced Therapy designation is one of FDA's best-known expedited pathways.
Read on Substack →
The Hillman Letter · 2026-06-13
The Pre-IND Meeting. What CBER Reviewers Actually Want to See.
Most sponsors treat the Pre-IND meeting as a regulatory introduction. CBER reviewers treat it as a compressed read of your CMC reality. The asymmetry costs sponsors millions in rework.
Read on Substack →
The Hillman Letter · 2026-08-11
Direct Biologics kills ExoFlo perianal fistula trial after enrolling five patients
Direct Biologics terminated its ExoFlo trial in perianal fistula (NCT05836883) on August 11.
Read on Substack →
The Hillman Letter · 2026-08-03
Paradigm Peptides Was the Warm-Up. The Tissue Grey Market Is the Real Target.
The grey market regenerative medicine days are numbered.
Read on Substack →

Archive: thehillmanletter.substack.com

Frequently asked questions

Advisory, answered.

What does Andrew Hillman do?
Andrew Hillman is a business consultant and strategic advisor for healthcare, biotech, and investor-backed ventures in Dallas, Texas. The practice covers growth consulting and regulatory strategy.
How do new clients start with Andrew Hillman?
New clients start with a short, paid Diagnostic Advisory Engagement. A brief qualifying exchange comes first to confirm fit. The diagnostic assesses growth performance and regulatory position together, and ends with a written strategy report and a live strategy session.
Does Andrew Hillman offer a free consultation?
No. There is a brief qualifying exchange to confirm fit, and then new clients begin with a paid Diagnostic Advisory Engagement. The diagnostic stands on its own and is not a sales call with a fee attached. The fee is set out in the proposal.
What is included in business growth consulting?
Work on revenue, margin, operating discipline, and decision quality, with the scope set in writing before the work begins.
What does regulatory strategy advisory cover?
Pathway mapping, milestone planning, pressure-testing clinical, operational, and compliance plans, and preparing leadership for FDA and CMS engagement. It is strategy support, not legal advice, and no regulatory outcome is promised.
Connect